





B1CTcu5 analogs as promising antimicrobial peptides, replacing the sequence cysteine

Anna Beatriz Toledo Borges¹, Janaína Texeira Costa de Pontes¹, Cesar Augusto Roque-Borda¹, Eduardo Festozo Vicente², Saulo Santesso Garrido³, Fernando Rogério Pavan¹ ¹Tuberculosis Research Laboratory, School of Pharmaceutical Science, São Paulo State University (UNESP). ²School of Sciences and Engineering, São Paulo State University (UNESP). ³Chemistry Institute, São Paulo State University (UNESP)

Introduction

Due to the increase in emergency diseases and bacterial resistance and the drop in the development of new drugs, it has become necessary to develop solutions for the treatment of these pathologies. AMPs have several mechanisms to combat pathogens, as their actions are performed from direct contact with bacterial membranes through the formation of amphipathic structures with the hydrophilic and hydrophobic regions in the opposite parts of the peptides. The B1CTcu5 peptide was originally isolated from the cutaneous secretion of the Indian frog, Clinotarsus curtipe, belongs to the Brevinin-1 family and has been shown to have potential activity against infectious bacteria. In our research, homologues of B1CTcu5 were synthesized due to the fact that in its original sequence it contains cysteine that present spontaneous reactions due to the presence of thiol groups, making it difficult to understand the exact sequence that shows the activity; to test the antimicrobial activity of the homologues, the bacteria Salmonella Typhi, Pseudomonas

Material and Methods Determination of Minimum Inhibitory Concentration (MIC90) Solid Phase Peptide Synthesis (SPSS) In column 1 - 150 uL Homologous peptide B1CTcu5 LB culture medium Serial Dissolution In columns 2 - 11 - 100 uL Solution 3 x DMF -3 x DMC Ninhydrin test 1mg/ml - 50 uL In column 12 - 200 uL homogenizer 2h 1 2 3 4 56 7 8 9 10 11 12 **Positive** Resine Aminoacid HOBt + Aminoacid sequence Coupling + DIC 3 x DMF 60000000000000 3 x DMC H 00000000000000 H0000000000000 DMF/ DCM 1:1 3 x DMF 3 x DMC Cleavege Salmonella Typhi Staphylococcus aureus 1 2 3 4 5 6 7 8 9 10 11 12 A O O O O O O O O O O O O O TFA (95%) Positive Negative TIS (2.5%) Read in the Desprotection of F-moc grup Water (2.5%) Post. Microplate 4-methypiperidine 20% in linhydrin test 60000000000000 Escherichia coli Pseudomonas aeruginosa DMF нооооооооооо spectrophotometer Abs 700 nm Leave it 1) LIAGLAANFLPQILSKIARKA 2) LIAGLAANFLPQILSKIARKS 100 uL overnight **\3**) LIAGLAANFLPQILSKIARKK **4**) LIAGLAANFLPQILKKIARKS.

Results and Discussion




Figure 1: HPLC-MS analysis of the LC-MS analysis; MS spectra and aminoacid sequence of B1CTcu5 homologous (antimicrobial peptide)

Purity of the peptide was 95% assessed by HPLC and confirmed by LC-MS

MIC-values

Compound	S. Tiphymurium	P. aeruginosa	S. aureus	E. coli
1-analog	31,25	> 62,5	125	> 62,5
2-analog	> 31,25	> 62,5	62,5	> 62,5
3-analog	> 31,25	> 62,5	62,5	> 62,5
4-analog	> 15,625	> 62,5	31,25	> 62,5

Table 1: MIC values of B1CTcu5 homologous (antimicrobial peptide) against S. Tiphy, P. aeruginosa, S. aureus, E.coli

All chromatographic profiles are shown in their impure form (just after cleavage), and mass spectrometric analysis represents the peak and retention time of the purified peptide. The purity of the peptide was greater than 95% and used for microbiological studies. The minimum inhibition concentrations in 96-well micro-silver were performed in triplicate. MIC-values between 15.6 - 62.5 µg/mol were obtained, which shows the efficiency of substituting cysteine for other amino acids such as alanine and lysine.

Conclusion

These result show that the B1CTcu5 analogs could possess an effective antimicrobial activity using variations and replacing the sequence cysteine.

References

ABRAHAM, P.; et al. KUMAR, K. S. B1CTcu5: A frog-derived brevinin-1 peptide with anti-tuberculosis activity. **Peptides**, [s. 1.], v. 132, p. 170373, 2020

ALMATAR, MANAF, et al. «Antimicrobial Peptides as an Alternative to Anti-Tuberculosis Drugs». Pharmacological **Research**, vol. 128, Fevereiro de 2018, pp. 288–305. DOI.org (Crossref), doi:10.1016/j.phrs.2017.10.011. ROQUE-BORDA, CESAR A., et al. «Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria». Pharmaceutics, vol. 13, n. 6, Maio de 2021, p. 773. DOI.org (Crossref), doi:10.3390/pharmaceutics13060773.

Acknowledgments

developed with the support of São Paulo Research This work was Foundation/FAPESP (Process number 2020/13497-4), PhD scholarship (2020/16573-3) and National Council for Scientific and Technological Development -Institutional Scientific Initiation Scholarship Program/ CNPq – PIBIC (136324/2021-5). We also thank the Institute of Chemistry - Araraquara (IQ-UNESP) for the use of measuring equipment, University of Araraquara who made available the use of the fluidized bed and ShinEtsu for kindly provide the coatings to the experiments and the research group "Peptides: Synthesis, Optimization and Applied Studies - PeSEAp"



The 7th International Electronic Conference on Medicinal Chemistry 01-30 NOVEMBER 2021 ONLINE